MDCG 2026-6: new guidance addresses clinical evidence for orphan IVDs

The Medical Device Coordination Group (MDCG) has published MDCG 2026-6 on clinical evidence for orphan in vitro diagnostic medical devices. The new guidance provides a framework for addressing the clinical evidence challenges associated with IVDs intended for rare diseases, conditions or circumstances (orphan devices). Under the In Vitro Diagnostic Medical Devices Regulation (IVDR), manufacturers must demonstrate sufficient clinical evidence to support an IVD’s safety and performance. For IVDs addressing very small patient populations, however, generating conventional levels of clinical performance data can be particularly challenging, notably because of limited availability of patients and specimens. MDCG 2026-6 recognises these constraints and sets out a more proportionate approach to clinical evidence, while maintaining the fundamental safety and performance requirements of the IVDR.

What qualifies as an orphan IVD?

For the purposes of the new MDCG guidance, an IVD may qualify as an orphan IVD where:

  • it is specifically intended to test persons for a disease, condition or circumstance occurring in no more than 12,000 individuals in the EU per year; and
  • there are insufficient available alternatives, or the IVD is expected to provide a clinical benefit compared with available alternatives or the state of the art.

Importantly, the 12,000-individual threshold relates to the incidence of the disease, condition or circumstance rather than to the number of tests performed. Manufacturers are expected to substantiate orphan status using appropriate epidemiological evidence and scientific justification.

The guidance also introduces the concept of an orphan indication. This applies where an IVD has an intended purpose for a small orphan population or subpopulation alongside another intended purpose covering a larger population. In these cases, the principles of the guidance may be applied specifically to the orphan indication, where appropriately justified.

A proportionate approach to clinical evidence

One of the most significant aspects of MDCG 2026-6 is its acknowledgement that the level of clinical evidence reasonably obtainable for an orphan IVD may differ from that expected for an IVD intended for a larger population. An orphan IVD may, under certain circumstances, be placed on the market despite limitations in the amount or quality of available pre-market clinical performance data. However, this does not remove the obligation to demonstrate conformity with the applicable General Safety and Performance Requirements (GSPRs).

A limited clinical performance dataset may be acceptable where, among other considerations:

  • all available data have been appropriately evaluated and remaining limitations identified;
  • the existing evidence is sufficient to demonstrate compliance with the relevant GSPRs and an acceptable benefit-risk profile;
  • obtaining further pre-market clinical performance data within an acceptable timeframe would not be feasible or proportionate;
  • appropriate post-market performance follow-up (PMPF) and post-market surveillance (PMS) activities are established to address remaining evidence gaps; and
  • users are adequately informed about the orphan status and limitations of the available pre-market clinical performance data.

High-quality non-clinical evidence

The guidance also highlights the role that high-quality non-clinical evidence can play when clinical performance data are difficult to obtain. Relevant sources may include scientific literature, analytical performance data from similar assays, patient registries and other datasets, in silico modelling and simulations, tissue or ex vivo models, contrived samples and data obtained from similar IVDs or research-use-only products. Where such evidence provides strong support for the safety, performance and expected clinical benefit of an orphan IVD, it may help reduce the amount of pre-market clinical performance data required, provided remaining limitations are appropriately addressed through PMS and PMPF activities.

Extrapolation of existing clinical data

MDCG 2026-6 addresses the possibility of extrapolating clinical performance data from a non-orphan population to an orphan indication. Whether such extrapolation is appropriate depends on factors including the similarity of the populations, statistical considerations, the quality of the underlying data and whether the extrapolated evidence constitutes valid scientific evidence. The guidance provides further considerations on this approach in Annex 3.

This may be particularly relevant for IVDs which already have a well-supported intended purpose in a larger population but are being extended to a rare disease or clinically distinct orphan subpopulation.

Post-market evidence becomes particularly important

Where limitations in pre-market clinical performance data are accepted, PMPF and PMS become central to the overall evidence strategy.

Manufacturers should establish plans capable of generating additional clinical performance data after market access and addressing identified evidence gaps as far as possible. Consequently, the orphan IVD approach should not be understood simply as accepting a smaller clinical dataset. It is instead a lifecycle approach, under which justified pre-market limitations are accompanied by continued evidence generation once the device is in use.

In-house IVDs under Article 5(5) IVDR

MDCG 2026-6 is also relevant to EU health institutions manufacturing and using in-house IVDs under Article 5(5) IVDR. Although such devices are exempt from most IVDR requirements, including certification, they must comply with the applicable GSPRs of Annex I. The general principles concerning orphan status, non-clinical evidence, generation of clinical performance data, justified limitations in those data and subsequent evidence generation may therefore also be relevant to in-house orphan IVDs.

Requirements specifically concerning notified bodies, CE marking, certification and expert-panel procedures do not apply to these in-house devices.

What does this mean for manufacturers?

For manufacturers of IVDs for rare conditions, MDCG 2026-6 provides an important pathway for building a proportionate clinical evidence strategy under the IVDR.

Manufacturers intending to rely on the orphan IVD approach should, in particular:

  • Establish and document orphan status, including robust epidemiological evidence supporting the 12,000-individual threshold.
  • Define the target population and intended purpose precisely, particularly where an orphan subpopulation or indication is claimed.
  • Document the unmet need or expected clinical benefit compared with available alternatives and the state of the art.
  • Evaluate all available clinical and non-clinical evidence, rather than considering limited specimen availability alone.
  • Clearly identify and justify gaps in pre-market clinical performance evidence.
  • Consider whether existing evidence can legitimately be extrapolated from other populations.
  • Develop robust PMS and PMPF plans capable of addressing outstanding clinical evidence limitations after market access.

MDR: clinical evaluation of orphan medical devices

In 2024, the MDCG (Medical Device Coordination Group) published MDCG 2024-10 on clinical evaluation of orphan medical devices under the EU MDR.


Contact MDlaw Team here for any questions on European regulations.

References

European Commission (2026). MDCG 2026-6 – Guidance on clinical evidence for orphan IVDs. Retrieved on 10 November 2026.

Leave a Reply

Your email address will not be published.